ENVIZION MEDICAL LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.8 ILa | 0.00% |
|
0.00% | -81.50% |
| 2023 | ENvizion Medical Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2021 | ENvizion Medical Ltd. has completed an IPO in the amount of ILS 20 million. | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 27.74 | 13.85 |
| Enterprise Value (EV) 1 | 25.36 | 14.06 |
| P/E ratio | -3.34 x | -1.85 x |
| Yield | - | - |
| Capitalization / Revenue | 51,555,548 x | 22,855,053 x |
| EV / Revenue | 47,129,897 x | 23,196,638 x |
| EV / EBITDA | -4.01 x | -1.72 x |
| EV / FCF | -8,851,380 x | -3,037,498 x |
| FCF Yield | -0% | -0% |
| Price to Book | 10.8 x | 29.8 x |
| Nbr of stocks (in thousands) | 2,215 | 2,572 |
| Reference price 2 | 12.52 | 5.386 |
| Announcement Date | 3/30/22 | 3/30/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net sales | - | - | 0.275 | 0.538 | 0.606 |
| EBITDA 1 | -2.318 | -3.256 | -4.381 | -6.329 | -8.16 |
| EBIT 1 | -2.381 | -3.327 | -4.48 | -6.39 | -8.286 |
| Operating Margin | - | - | -1,629.09% | -1,187.73% | -1,367.33% |
| Earnings before Tax (EBT) 1 | -2.406 | -3.362 | -5.338 | -7.081 | -7.624 |
| Net income 1 | -2.406 | -3.362 | -5.338 | -7.091 | -7.631 |
| Net margin | - | - | -1,941.09% | -1,318.03% | -1,259.24% |
| EPS 2 | -3.043 | -2.925 | -3.789 | -3.750 | -2.909 |
| Free Cash Flow | - | -2.501 | -2.182 | -2.865 | -4.628 |
| FCF margin | - | - | -793.55% | -532.46% | -763.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/8/21 | 2/8/21 | 5/6/21 | 3/30/22 | 3/30/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 2.64 | - | 0.21 |
| Net Cash position 1 | 0.13 | 0.52 | - | 2.38 | - |
| Leverage (Debt/EBITDA) | - | - | -0.6019 x | - | -0.0254 x |
| Free Cash Flow | - | -2.5 | -2.18 | -2.86 | -4.63 |
| ROE (net income / shareholders' equity) | - | -434% | 1,431% | -3,166% | -489% |
| ROA (Net income/ Total Assets) | - | -173% | -142% | -127% | -135% |
| Assets 1 | - | 1.943 | 3.769 | 5.588 | 5.667 |
| Book Value Per Share 2 | 0.1800 | 1.060 | -1.490 | 1.160 | 0.1800 |
| Cash Flow per Share 2 | 0.3600 | 0.4900 | 0.6900 | 1.060 | 0.1000 |
| Capex 1 | 0.02 | 0.06 | 0.08 | 0.04 | 0.59 |
| Capex / Sales | - | - | 30.55% | 8.18% | 97.19% |
| Announcement Date | 2/8/21 | 2/8/21 | 5/6/21 | 3/30/22 | 3/30/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- ENVM-L Stock
- Financials ENvizion Medical Ltd.
